Factors influencing ocular pain in patients with dry eye in Tibet

News
Article

The retrospective study investigated and analyzed the severity and frequency of ocular pain and factors affecting it among DED patients living in high altitudes above 2500 meters during the COVID-19 pandemic.

Tibetan flags on mountainside Image credit: AdobeStock/mrallen

Image credit: AdobeStock/mrallen

A Chinese study1 led by co-authors Peng-Cheng Zhang, MD, PhD, and Wen-Shan Jiang , a PhD candidate, reported that ocular pain is a relatively common complaint in patients with dry eye disease (DED) living on the Tibetan plateau. The ocular pain was associated significantly with COVID-19 epidemic-induced anxiety, professional protection for the eyes, and adequate sleep are associated significantly with the severity and frequency of ocular pain.

The researchers are from the Department of Ophthalmology, General Hospital of Central Theater Command, Fundus Laser Clinical Research Center of Hubei Province, Wuhan, China; and the Shaanxi Eye Hospital, Xi’an People’s Hospital (Xi’an Fourth Hospital), Affiliated People’s Hospital of Northwest University, Xi’an, China.

They explained that during COVID-19, individuals environmental and lifestyle changes, ie, frequent indoor sterilization, increased use of video terminals, long-term mask wearing, and anxiety stress triggered/exacerbated DED.2,3

Special circumstances must be considered for plateau dwellers, such as Tibetans, mountaineers, and garrison officers, who are exposed to low humidity, strong ultraviolet rays, cold and dry weather, and low pressure and hypoxia, the authors pointed out.

“The eyes are the first to suffer and are vulnerable to damage, with DED the most common,4” they stated. At high altitudes bodily functions are affected significantly affected, and the prevalence of plateau DED is 26.1%, which is significantly higher than that (11.9%) at lower altitudes.5 

“Ocular pain is one of the important symptoms of DED, but its incidence in patients with DED is unknown. The physical sensation of ocular pain varies with each individual and can be complained of as burning, discomfort, gritty sensation or stinging pain,6 which is difficult to characterize accurately. However, the degree and frequency of ocular pain can significantly affect patients’ quality of life and reduce treatment compliance.7 Therefore, it is crucial to understand the ocular pain among DED patients and its influencing factors, which will facilitate the adoption of individualized therapy strategies,” the researchers commented.

They therefore designed a retrospective study to investigate and analyze the severity and frequency of ocular pain and factors affecting it among DED patients living in high altitudes above 2500 meters during the COVID-19 pandemic.

The study included 160 DED patients treated from July 2022 to June 2023. The factors collected and studied were age, gender, occupation, illness course, anxiety, plateau duration, plateau protection, ocular surface disease index scale (OSDI), break-up time, Schirmer I test, conjunctivitis, history of ophthalmic medication, autoimmune disease, the workload of daily near vision range, smoking and overnight stay were obtained via comprehensive ophthalmic assessment, and their duration.

Results found at high altitudes

The data analysis showed that 77.5% of DED patients had ocular pain, that ranged in severity from mild, moderate, and severe in 30.0%, 36.3%, and 11.3%, respectively.

The patient-reported frequencies of ocular pain that were described as occasional, half the time, frequent, and persistent were 19.4%, 36.9%, 16.9%, and 4.4%, respectively.

The mean OSDI score was 19.67±5.70 (range, 13-36), and the level of pain was correlated with the OSDI (rs value, 0.316, p<0.001). Logistic regression analysis showed that patients with DED living at a high altitude experienced increased anxiety, which led to increased severity and frequency of ocular pain (odds ratio [OR], severity, 3.662 (mild anxiety), 5.613 (severe anxiety); frequency, 2.387 (mild anxiety), and 4.870 (severe anxiety) (p<0.05 for all comparisons).

The use of professional eye protection and improved daily sleep quantity decreased the severity and frequency of the ocular pain (severity, OR, 0.307, 0.572; frequency, 0.418 and 0.789 (p<0.05 for all comparisons). Smoking and the general protection of the plateau did not affect the severity and frequency of the ocular pain (P>0.05 for all comparisons), the investigators reported.

The authors summarized, “Complaints of ocular pain are relatively common in DED patients on the plateau. Epidemic-induced anxiety, professional protection for the eye, and adequate sleep are significantly associated with the severity and frequency of ocular pain in dry eye patients, while the effect of dry eye symptoms was relatively weak.”

References:
  1. Peng-Cheng Zhang, Wen-Shan Jiang, Ya-Zhen Wu, et al. Influencing factors of ocular pain in dry eye disease patients at high altitude. Int J Ophthalmol. 2024,17:2214-2220.
  2. Barabino S. A narrative review of current understanding and classification of dry eye disease with new insights on the impact of dry eye during the COVID-19 pandemic. Ophthalmol Ther. 2021;10:495-507.
  3. Koh S, Rhee MK. COVID-19 and dry eye. Eye Contact Lens. 2021;47:317-322.
  4. Liu BJ, Jiang SS, Li ZY, Wang Y, Zhou DJ, Chen Z. Investigation and analysis of eye discomfort caused by video display terminal use among medical students studying at high-altitude regions. Front Public Health. 2022;10:900539.
  5. Zheng C, Yang YY, Shu YK, et al. Research on dry eye incidence in plateau training or plain encamping soldiers. Med J National Def Forces Southwest Chin. 2016;26:1521-1523.
  6. Kalangara JP, Vanijcharoenkarn K, Chisolm S, Kuruvilla ME. Neuropathic pain and itch: mechanisms in allergic conjunctivitis. Curr Opin Allergy Clin Immunol. 2022;22:298-303.
  7. Dieckmann G, Borsook D, Moulton E. Neuropathic corneal pain and dry eye: a continuum of nociception. Br J Ophthalmol. 2022;106:1039-1043.
Recent Videos
Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.
Neda Gioia, OD, CNS, FOWNS, details the positive feedback gained so far from other optometrists that have been prescribing the NutriTears supplement to their dry eye patients.
Damaris Raymondi, OD, FAAO, highlighted the importance of building patient-doctor trust to learn about these practices, which can include non-traditional treatments like chamomile or manuka honey eye drops.
Noreen Shaikh, OD, Magdalena Stec, OD, FAAO, and Brenda Bohnsack, MD, PhD, emphasize that collaboration and communication are key to proper diagnosis and treatment.
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Kerry Giedd, OD, MS, FAAO, was 1 of 20 investigators around the country for a study evaluating the daily disposable contact lens.
According to A. Paul Chous, MA, OD, FAAO, optometrists have an important opportunity to educate patients in their chairs about diabetes.
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
Jessica Steen, OD, FAAO, Dipl-ABO, discussed ophthalmic considerations for patients undergoing treatment with antibody drug conjugates for gynecologic cancers at this year's conference.
A. Paul Chous, MA, OD, FAAO, details a presentation on this year's updates on diabetes given at this year's Academy meeting
© 2024 MJH Life Sciences

All rights reserved.